Inscripta, founded in 2015 by Andrew Garst, Ryan T Gill and Tanya Lipscomb, provides gene editing tools for academic and commercial customers.In 2018 Inscripta acquired Solana Biosciences, a life sciences company founded by veterans of Illumina . Expansion plans include a new office in the life sciences hub of San Diego.
Inscripta has an enzyme engineering program rather than a particular application and they aim to provide tools for their customers to create their own applications faster.To tackle the lack of access and high cost of CRISPR gene-editing enzymes Inscripta is engineering CRISPR endonucleases called MADzymes.The DNA sequence for one MADzyme, MAD7 is provided free for any R&D use without reach-through royalty rights.MAD7 is derived from the genome of Eubacterium rectale and is a codon-optimized nuclease similar to Cpf1 (Cas12a). Inscripta is also engineering novel enzymes for exclusive use by industry partners.
Chief Technical Officer
Documentaries, videos and podcasts
- CRISPRClustered regularly interspaced short palindromic repeats (CRISPR) is a prokaryotic adaptive immune response that provides immunity against foreign nucleic acids, such as viral DNA and bacterial plasmids, through the use of crRNAs (CRISPR RNAs) and associated Cas genes.
- CRISPR-Cas12aCRISPR-Cas12a is is a genome editing tool similar to CRISPR-Cas9. CRISPR-Cas12a is a set of RNA guided DNA targeting proteins capable of producing targeted double-stranded DNA (dsDNA) breaks, targeted single-stranded DNA breaks, and indiscriminate ssDNA degradation in trans. The effector protein Cas12a is also known at Cpf1.